Literature DB >> 30556332

Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel.

F Yuen1, S Wu2, A Thirumalai2, R S Swerdloff1, S T Page2, P Y Liu1, C Dart3, H Wu3, D L Blithe4, R Sitruk-Ware5, J Long4, F Bai1, L Hull1, W J Bremner2, B D Anawalt2, C Wang1.   

Abstract

BACKGROUND: Testosterone (T)/Nestorone (NES) combination gel is a potential transdermal male contraceptive that suppresses gonadotropins and spermatogenesis. Transfer of transdermal T from men to women can be prevented by washing or covering application sites with clothing.
OBJECTIVES: We hypothesized that showering or wearing a shirt over gel application sites would prevent secondary exposure of T and NES to a woman after close skin contact.
MATERIALS AND METHODS: Twelve healthy male and 12 healthy female participants were recruited. Men applied T/NES 62 mg/8 mg gel to their shoulders and upper arms. Two hours after application, female partners rubbed the application site for 15 min. Exposure in the female partner was assessed under three conditions: a shirt covered the application site; the man showered prior to skin contact; or without intervention to reduce transfer. Serum T and NES concentrations were measured by LC-MS/MS in serial blood samples for 24 h after gel exposure. MAIN OUTCOMES: Change in female serum T and NES levels as measured by average concentration over 24 h (Cavg ).
RESULTS: Median female serum T Cavg was 23.9 ng/dL (interquartile range, 19.3, 33.9) with the shirt barrier and 26.7 ng/dL (20.7, 33.9) after showering, which was higher than baseline 20.9 ng/dL (16.7, 25.0), both p < 0.03) but lower than without intervention (58.2 ng/dL [30.9, 89.1], both p < 0.01). Female serum NES Cavg and maximum concentration were below the lower limit of quantification with the shirt barrier and after showering, but increased without intervention in six of 12 women (maximum concentration <60 pg/mL). Men had lower average serum NES levels after showering (47 pg/ml [20, 94] compared to no intervention (153.3 pg/mL [51, 241], p < 0.02).
CONCLUSION: Secondary transfer of T and NES occurs after intensive skin contact with the gel application site. Secondary transfer is decreased by a shirt barrier or showering before contact.
© 2018 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  androgen; male contraceptive; nestorone; progestin; skin transfer; transdermal gels

Mesh:

Substances:

Year:  2018        PMID: 30556332      PMCID: PMC6422752          DOI: 10.1111/andr.12577

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   4.456


  28 in total

Review 1.  A review of androgen-progestin regimens for male contraception.

Authors:  M Cristina Meriggiola; Timothy M M Farley; Michael T Mbizvo
Journal:  J Androl       Date:  2003 Jul-Aug

Review 2.  Male hormonal contraception.

Authors:  Christina Wang; Ronald S Swerdloff
Journal:  Am J Obstet Gynecol       Date:  2004-04       Impact factor: 8.661

3.  Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.

Authors: 
Journal:  Fertil Steril       Date:  1996-04       Impact factor: 7.329

4.  Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.

Authors:  J T Jensen; A B Edelman; B A Chen; D F Archer; K T Barnhart; M A Thomas; A E Burke; C L Westhoff; L S Wan; R Sitruk-Ware; N Kumar; B Variano; D L Blithe
Journal:  Contraception       Date:  2018-02-02       Impact factor: 3.375

5.  Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry.

Authors:  Steve Shiraishi; Paul W N Lee; Andrew Leung; Victor H H Goh; Ronald S Swerdloff; Christina Wang
Journal:  Clin Chem       Date:  2008-09-18       Impact factor: 8.327

6.  A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women.

Authors:  Vivian Brache; Ruth Merkatz; Narender Kumar; Cristian Jesam; Heather Sussman; Elena Hoskin; Kevin Roberts; Mohcine Alami; Deshawn Taylor; Aidelis Jorge; Horacio Croxatto; Ellen Lorange; Daniel R Mishell; Regine Sitruk-Ware
Journal:  Contraception       Date:  2015-05-29       Impact factor: 3.375

Review 7.  Nestorone: clinical applications for contraception and HRT.

Authors:  Regine Sitruk-Ware; Margaret Small; Narender Kumar; Yun-Yen Tsong; Kalyan Sundaram; Theodore Jackanicz
Journal:  Steroids       Date:  2003-11       Impact factor: 2.668

8.  Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men.

Authors:  Vahid Mahabadi; John K Amory; Ronald S Swerdloff; William J Bremner; Stephanie T Page; Regine Sitruk-Ware; Peter D Christensen; Narender Kumar; Yun-Yen Tsong; Diana Blithe; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2009-04-14       Impact factor: 5.958

9.  Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility.

Authors: 
Journal:  Lancet       Date:  1990-10-20       Impact factor: 79.321

Review 10.  Male Hormonal Contraception: Where Are We Now?

Authors:  Christina Wang; Mario P R Festin; Ronald S Swerdloff
Journal:  Curr Obstet Gynecol Rep       Date:  2016-01-29
View more
  3 in total

1.  Simultaneous assay of segesterone acetate (Nestorone®), estradiol, progesterone, and estrone in human serum by LC-MS/MS.

Authors:  David W Erikson; Steven W Blue; Kristopher M Fecteau; Alison B Edelman; Jeffrey T Jensen; Diana L Blithe
Journal:  Contraception       Date:  2020-08-21       Impact factor: 3.375

2.  Hormonal Male Contraception: Getting to Market.

Authors:  Stephanie T Page; Diana Blithe; Christina Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-03       Impact factor: 6.055

Review 3.  Continuing the search for a hormonal male contraceptive.

Authors:  Fiona Yuen; Brian T Nguyen; Ronald S Swerdloff; Christina Wang
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2020-02-19       Impact factor: 5.237

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.